Sponsor
- Home
- Your Messages
-
Smartest Doc
Daily Quiz CompetitionTest your clinical knowledge against other physicians in the USA by taking our FREE daily quiz!
New! PHYSICIAN REVIEW
Thousands of questions to assess your knowledge and aid exam prep!
- Physician Jobs (2021)
- More
- Other Specialty
Phase I study of sorafenib in combination with docetaxel and prednisone in chemo-naive patients with metastatic castration-resistant prostate cancer
Cancer Chemotherapy and Pharmacology, 07/05/2012
Mardjuadi F et al. – Three–weekly docetaxel and prednisone could be combined with sorafenib at 400mg BID on days 1–21 without reaching Maximal tolerated dose (MTD). However, the authors observed a pharmacokinetic interaction between sorafenib and docetaxel, associated with significant toxicities, raising concerns about the safety of this combination in metastatic castration–resistant prostate cancer (mCRPC).
Register now to view all the MDLinx contents (FREE)!
- Stay current on the latest literature, research and clinical news
- Get special communications and offers from MDLinx and our sponsors
- Receive invitations to paid market research
Login
Sponsor
Stay current - Media Tool
♦ Subscribe to our free RSS feeds:
Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More ♦
♦ Follow Us on Twitter
Twitter is a rich source of instantly updated information. Join today and follow @MDLinx to start receiving tweets. Learn More ♦
Close
Sponsor